Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
DAVID VOLK, MD, PHD
TRANSLATIONAL NEUROSCIENCE PROGRAM
UNIVERSITY OF PITTSBURGH
Exploring the Relationship Between
Cannabi...
Cannabis Use and Schizophrenia
Associated with worse clinical outcome
 Kavanagh Drugs 2002
Prefrontal cortex-related co...
Endocannabinoid (eCB) System
CB1 receptor is
located on inhibitory
axon terminals
Activation of the CB1
receptor suppres...
Endocannabinoid (eCB) System and Schizophrenia
GABA signaling is already impaired in the PFC in
schizophrenia which contr...
What is the status of eCB signaling in schizophrenia?
Lower CB1 receptor mRNA and protein levels in the PFC in
schizophre...
2-AG: The Brain’s Own Cannabis
2-AG (2-arachidonyloglycerol) is an endogenous
cannabinoid
2-AG is synthesized by diacylg...
Endocannabinoid Signaling Suppresses GABA Release
Subject Demographics
Control Schizophrenia T Value
(df=82)
P Value
N 42 42
Sex 31M/11F 31M/11F
Race 34W/8B 29W/13B
Age (ye...
Project Design
Real-time reverse transcription PCR (quantitative PCR)
RNA isolated from PFC area 9
RNA is reversed tran...
2-AG Synthesizing and Metabolizing Enzymes
DAGLα DAGLβ MGL
ANCOVA F Stat P Value F Stat P Value F Stat P Value
F1,38 .019 ...
Metabolizing Enzyme for Anandamide
FAAH
ANCOVA F Stat P Value
F1,38 1.1 .30
RelativeExpressionLevelinSchiz
Relative Expres...
Group I Metabotropic Glutamate Receptors
mGluR1α mGluR5
ANCOVA F Stat P Value F Stat P Value
F1,38 9.2 .004 3.5 .07
+12.4%...
Summary of Findings
No change in 2-AG or anandamide synthesizing or
metabolizing enzyme mRNA expression levels in
PFC are...
Validation of Results with Additional Primers
Primer Set %
Change
in Schiz
Unpaired (F1,16) Paired (F1,8)
F P F P
mGluR1α_...
Interpreting Elevated mGluR1α mRNA
Expression in Schizophrenia
Elevated signaling through mGluR1α receptors may
increase ...
RGS4 and mGluR1α in Schizophrenia
RGS4 (Regulator of G Protein Signaling) reduces the
duration of signaling from some G p...
RGS4 mRNA Expression in Schizophrenia
ANCOVA F Stat P Value
F1,38 29.4 .000
-16.1%
RelativeExpressionLevelinSchizophrenia
...
Interpreting Elevated mGluR1α mRNA
Expression in Schizophrenia
Are elevated mGluR1α mRNA levels associated with
enhanced ...
Novel Treatment Approaches for Schizophrenia
mGluR1α antagonist may reduce eCB-mediated
suppression of GABA signaling
 m...
Acknowledgements
David Lewis, MD, Director of the Translational
Neuroscience Program
Translational Neuroscience Program ...
Questions and Comments?
Future Studies
Cannabis use during adolescence is a risk factor for
schizophrenia
 Moore Lancet 2007
Mechanism of incre...
Upcoming SlideShare
Loading in …5
×

Endocannabinoid Signaling in the Prefrontal Cortex in Schizophrenia

745 views

Published on

  • Be the first to comment

Endocannabinoid Signaling in the Prefrontal Cortex in Schizophrenia

  1. 1. DAVID VOLK, MD, PHD TRANSLATIONAL NEUROSCIENCE PROGRAM UNIVERSITY OF PITTSBURGH Exploring the Relationship Between Cannabis Use, Cognitive Deficits and Schizophrenia: Role of the Endogenous Cannabinoid System
  2. 2. Cannabis Use and Schizophrenia Associated with worse clinical outcome  Kavanagh Drugs 2002 Prefrontal cortex-related cognitive impairments  Solowoji JAMA 2002 Exacerbates cognitive impairments in schizophrenia  D’Souza BiolPsych 2005
  3. 3. Endocannabinoid (eCB) System CB1 receptor is located on inhibitory axon terminals Activation of the CB1 receptor suppresses the release of GABA
  4. 4. Endocannabinoid (eCB) System and Schizophrenia GABA signaling is already impaired in the PFC in schizophrenia which contributes to cognitive deficits in schizophrenia Cannabis use may worsen cognitive deficits in schizophrenia by aggravating pre-existing deficits in GABA signaling Alterations in eCB signaling may worsen impairments in GABA signaling in schizophrenia
  5. 5. What is the status of eCB signaling in schizophrenia? Lower CB1 receptor mRNA and protein levels in the PFC in schizophrenia (Eggan ArchGenPsych 2008) Knowing the status of eCB signaling requires knowledge of the regulation of the eCB ligands that bind to the CB1 receptor
  6. 6. 2-AG: The Brain’s Own Cannabis 2-AG (2-arachidonyloglycerol) is an endogenous cannabinoid 2-AG is synthesized by diacylglycerol lipase (DAGL) 2-AG is metabolized by monoglyceride lipase (MGL) 2-AG activates CB1 receptors and reduces the release of GABA
  7. 7. Endocannabinoid Signaling Suppresses GABA Release
  8. 8. Subject Demographics Control Schizophrenia T Value (df=82) P Value N 42 42 Sex 31M/11F 31M/11F Race 34W/8B 29W/13B Age (years) 48 ± 13 47 ± 13 0.4 p=0.69 PMI (hours) 17.8 ± 5.9 18.1 ± 8.7 .17 p=0.86 Storage (mo) 97 ± 43 97 ± 46 .02 p=0.98 pH 6.7 ± 0.2 6.6 ± 0.4 1.67 p=.10 RIN 8.3 ± 0.6 8.2 ± 0.7 1.2 p=.23
  9. 9. Project Design Real-time reverse transcription PCR (quantitative PCR) RNA isolated from PFC area 9 RNA is reversed transcribed to cDNA Quantitative PCR performed with SYBR Green and gene- specific primers Gene expression levels normalized to 3 reference genes
  10. 10. 2-AG Synthesizing and Metabolizing Enzymes DAGLα DAGLβ MGL ANCOVA F Stat P Value F Stat P Value F Stat P Value F1,38 .019 .89 .018 .90 .841 .37 Relative Expression Level in Control Subjects RelativeExpressionLevelinSchiz
  11. 11. Metabolizing Enzyme for Anandamide FAAH ANCOVA F Stat P Value F1,38 1.1 .30 RelativeExpressionLevelinSchiz Relative Expression Level in Control Subjects
  12. 12. Group I Metabotropic Glutamate Receptors mGluR1α mGluR5 ANCOVA F Stat P Value F Stat P Value F1,38 9.2 .004 3.5 .07 +12.4% +4.3% RelativeExpressionLevelinSchiz Relative Expression Level in Control Subjects
  13. 13. Summary of Findings No change in 2-AG or anandamide synthesizing or metabolizing enzyme mRNA expression levels in PFC area 9 in schizophrenia.  However, we do not know if changes may be still be present at the protein level (i.e. amount and/or activity of enzyme). Elevated mGluR1α mRNA expression levels in the PFC in schizophrenia.
  14. 14. Validation of Results with Additional Primers Primer Set % Change in Schiz Unpaired (F1,16) Paired (F1,8) F P F P mGluR1α_1 +38.8% 38.5 .000 37.6 .000 mGluR1α_2 +39.9% 39.1 .000 91.3 .000 mGluR1α_3 +30.7% 26.8 .000 57.2 .000
  15. 15. Interpreting Elevated mGluR1α mRNA Expression in Schizophrenia Elevated signaling through mGluR1α receptors may increase 2-AG signaling, resulting in a further deleterious reduction in GABA neurotransmission in the PFC in schizophrenia. Are elevated mGluR1α mRNA levels associated with enhanced signaling through the receptor?  Elevated mGluR1α protein levels (and no change in mGluR5) previously reported in the PFC in schizophrenia (Gupta Synapse 2005).
  16. 16. RGS4 and mGluR1α in Schizophrenia RGS4 (Regulator of G Protein Signaling) reduces the duration of signaling from some G protein coupled receptors, including mGluR1α (Saugstad JNeurosci 1998). Lower RGS4 mRNA levels have been reported in the PFC in schizophrenia (Mirnics MolPsych 2001, Erdely Synapse 2006). Lower RGS4 and higher mGluR1α levels may together further enhance signaling through mGluR1α receptors in the PFC.
  17. 17. RGS4 mRNA Expression in Schizophrenia ANCOVA F Stat P Value F1,38 29.4 .000 -16.1% RelativeExpressionLevelinSchizophrenia Relative Expression Level in Control Subjects *8 pairs previously studied
  18. 18. Interpreting Elevated mGluR1α mRNA Expression in Schizophrenia Are elevated mGluR1α mRNA levels associated with enhanced signaling through the receptor?  Elevated mGluR1α protein levels (and no change in mGluR5) previously reported in the PFC in schizophrenia (Gupta Synapse 2005).  The combination of lower RGS4 and higher mGluR1α levels may together further enhance signaling through mGluR1α receptors in the PFC.
  19. 19. Novel Treatment Approaches for Schizophrenia mGluR1α antagonist may reduce eCB-mediated suppression of GABA signaling  mGluR1α /5 activation induces LTP/LTD of AMPA and NMDA receptors (Ireland and Abraham JNeuroPhys 2009) DAGL inhibitor would reduce suppression of GABA release  Specific for 2-AG and not other eCB ligands
  20. 20. Acknowledgements David Lewis, MD, Director of the Translational Neuroscience Program Translational Neuroscience Program Faculty and Staff Liz Sengupta
  21. 21. Questions and Comments?
  22. 22. Future Studies Cannabis use during adolescence is a risk factor for schizophrenia  Moore Lancet 2007 Mechanism of increased sensitivity to the effects of cannabis during adolescence is not understood Knowledge of the development of the eCB system in the PFC may provide insights into mechanisms that lead to a period of increased sensitivity to cannabis

×